Abstract
Thyroid hormones regulate fundamental genes involved in the metabolism, development and homeostasis of vertebrates. The endogenous hormones, L-3, 5, 3-triiodo-L-thyronine (T3) and L-3, 5, 3, 5-tetraiodo-L-thyronine (T4), are of limited use in pharmacological intervention, mainly due to cardiovascular liabilities. There exist two subtypes of thyroid hormone receptors (TR), α and β, unequally distributed in the body. As TRα is most abundant in the heart and most effects of thyroid hormones on the heart are mediated through TRα, a reasonable strategy is the development of TR agonists that either are tissue selective or that interact selectively with TRβ. The prospects for the treatment of metabolic diseases with such ligands are considerable and this review describes the massive efforts of the academic and industrial communities during the last decade. It is, however, the authors view that the development of selective ligands only is in its infancy, an opinion highlighted by the limited chemical structural variation of TR ligands as well as the present lack of TR ligands for the treatment of metabolic diseases in clinical phases.
Keywords: thyroid hormones, thyroid hormone receptors, dyslipidemia, diabetes, hypothyroidism, obesity, atherosclerosis, metabolic diseases
Current Pharmaceutical Design
Title: Thyroid Hormone Ligands and Metabolic Diseases
Volume: 10 Issue: 28
Author(s): Johan Malm
Affiliation:
Keywords: thyroid hormones, thyroid hormone receptors, dyslipidemia, diabetes, hypothyroidism, obesity, atherosclerosis, metabolic diseases
Abstract: Thyroid hormones regulate fundamental genes involved in the metabolism, development and homeostasis of vertebrates. The endogenous hormones, L-3, 5, 3-triiodo-L-thyronine (T3) and L-3, 5, 3, 5-tetraiodo-L-thyronine (T4), are of limited use in pharmacological intervention, mainly due to cardiovascular liabilities. There exist two subtypes of thyroid hormone receptors (TR), α and β, unequally distributed in the body. As TRα is most abundant in the heart and most effects of thyroid hormones on the heart are mediated through TRα, a reasonable strategy is the development of TR agonists that either are tissue selective or that interact selectively with TRβ. The prospects for the treatment of metabolic diseases with such ligands are considerable and this review describes the massive efforts of the academic and industrial communities during the last decade. It is, however, the authors view that the development of selective ligands only is in its infancy, an opinion highlighted by the limited chemical structural variation of TR ligands as well as the present lack of TR ligands for the treatment of metabolic diseases in clinical phases.
Export Options
About this article
Cite this article as:
Malm Johan, Thyroid Hormone Ligands and Metabolic Diseases, Current Pharmaceutical Design 2004; 10 (28) . https://dx.doi.org/10.2174/1381612043382873
DOI https://dx.doi.org/10.2174/1381612043382873 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine Modulators of the Vascular Endothelin Receptor in Blood Pressure Regulation and Hypertension
Current Molecular Pharmacology Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews Functional Polymeric Nano/Microparticles for Surface Adsorption and Delivery of Protein and DNA Vaccines
Current Drug Delivery Is Renalase a Novel Player in Catecholaminergic Signaling? The Mystery of the Catalytic Activity of an Intriguing New Flavoenzyme
Current Pharmaceutical Design Heart Failure Pharmacotherapy: Differences Between Adult and Paediatric Patients
Current Medicinal Chemistry Beta-arrestin Biased Agonism/Antagonism at Cardiovascular Seven Transmembrane-spanning Receptors
Current Pharmaceutical Design Editorial [“Current Aging Science”: An Important Platform for Reporting Advances in Aging-related Research]
Current Aging Science Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design Associations between Alzheimer’s Disease and Blood Homocysteine, Vitamin B<sub>12</sub>, and Folate: A Case-Control Study
Current Alzheimer Research Cardiorenal Consequences of Atherosclerosis and Statins Therapy: From the Past to the Future
Current Pharmaceutical Design Sunlight Vitamin D and Skin Cancer
Anti-Cancer Agents in Medicinal Chemistry Lipid Modulation of Intravascular and Cellular Sodium Handling:Mechanistic Insights and Potential Clinical Implications
Current Vascular Pharmacology Evaluation of the Anti-Hypercholesterolemic and Antioxidant Activity of Mentha pulegium (L.) Aqueous Extract in Normal and Streptozotocin- Induced Diabetic Rats
The Natural Products Journal ATP-Binding Cassette Transporters A1 and G1, HDL Metabolism, Cholesterol Efflux, and Inflammation: Important Targets for the Treatment of Atherosclerosis
Current Drug Targets Nothing But Stress – The Interplay of Angiotensin II, Inflammation, Hypertension and Atherosclerosis: Implications for Atherosclerotic Plaque Stability
Vascular Disease Prevention (Discontinued) Adenosine A<sub>3</sub> Receptor: A promising therapeutic target in cardiovascular disease
Current Cardiology Reviews Stem Cells as In Vitro Models of Disease
Current Stem Cell Research & Therapy Patent Selections:
Recent Patents on Regenerative Medicine